Samuel J. Klempner, MD
Director, Precision Medicine Program, The Angeles Clinic and Research Institute, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, USA
Dr. Klempner is a clinical and translational researcher with a focus on experimental therapeutics in solid tumors, particularly gastrointestinal malignancies. Dr. Klempner completed his residency in internal medicine at Brigham and Women’s Hospital/Harvard Medical School, followed by a combined hematology-oncology fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School. While at Harvard Dr. Klempner studied the mechanisms of resistance to targeted therapies in tumor cells in the lab of Dr. Lewis Cantley, PhD. He served as an Assistant Professor at the University of California Irvine (2013-2016) prior to joining The Angeles Clinic. His research has been presented at major international meetings including the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), the American Association for Cancer Research (AACR), and published in prestigious journals such as the Journal of Clinical Oncology (JCO), Cancer Discovery, JAMA Oncology, Annals of Oncology and others. Dr. Klempner is active in SWOG and serves on several NIH committees. His present interests include defining molecular subtypes in gastric and other GI cancers, mechanisms of resistance to targeted therapies, early phase clinical trials and the intersection of genomics and immunotherapy.